ABSTRACT: Cytosolic phospholipase A 2 (GIVA cPLA 2 ) has attracted great interest as a medicinal target because it initiates the eicosanoid cascade and is involved in a number of inflammatory diseases. As a consequence, the development of potent synthetic inhibitors is of great importance. We have developed highly potent 2-oxoester inhibitors of GIVA cPLA 2 presenting X I (50) values between 0.000019 and 0.000066. We demonstrate that the 2-oxoester functionality is essential for in vitro inhibitory activity, making these inhibitors useful research reagents. However, their high reactivity results in rapid degradation of the inhibitors in human plasma, limiting their pharmaceutical utility without further modification.
■ INTRODUCTION
Phospholipases A 2 (PLA 2 s) have attracted great interest as medicinal targets for more than 20 years because they are involved in a number of inflammatory diseases. 1 Among this superfamily of enzymes, 2 cytosolic PLA 2 (GIVA cPLA 2 ) stands out because it exhibits a marked preference for the hydrolysis of arachidonic acid at the sn-2 position of phospholipid substrates releasing arachidonic acid and initiating the eicosanoid cascade. 3 Both the physiological function and the role of cytosolic PLA 2 have been recently summarized by Leslie. 4 Due to the involvement of PLA 2 s in various inflammatory diseases, many synthetic inhibitors have been developed in both academia and pharmaceutical companies. 1 Two recent review articles discuss the classes of PLA 2 inhibitors and highlight the in vitro activities and selectivity and the in vivo studies in animal models. 5, 6 Most recently, a randomized double-blind placebo-controlled dose-escalation first-in-man study to assess the safety and efficacy of a topical cytosolic PLA 2 inhibitor AVX001 (1, Figure 1 ) in patients with mild-to-moderate plaque psoriasis has demonstrated that treatment with AVX001 is well tolerated in doses up to 5%. 7 Pharmacological inhibition of GIVA cPLA 2 by inhibitor 2 ( Figure 1 ) blocked Streptococcus pneumoniaeinduced polymorphonuclear cells transepithelial migration in vitro, suggesting that this enzyme plays a crucial role in eliciting pulmonary inflammation during pneumococcal infection. 8 The daily administration of the indole-based inhibitor ASB14780 (3, Figure 1 ), which had been developed by Tomoo and colleagues, 9 markedly ameliorated liver injury and hepatic fibrosis following 6 weeks of treatment with CCl 4 , indicating that a GIVA cPLA 2 inhibitor could be useful for the treatment of nonalcoholic fatty liver diseases, including fatty liver and hepatic fibrosis. 10 A few years ago, we presented new thiazolyl ketones as inhibitors of GIVA cPLA 2 and demonstrated the in vivo anti-inflammatory activity of inhibitor GK470 (4, Figure 1 ) in a collagen-induced arthritis model. 11 The anti-angiogenic effects of this inhibitor (now named as AVX235) in a patient-derived triple-negative basal-like breast cancer model was evaluated and significant tumor growth inhibition was observed after 8 days of treatment. 12 Most recent findings showed that blockage of GIVA cPLA 2 by either inhibitor 2 or pyrrophenone (5, Figure 1 ) sensitized aggressive breast cancer to doxorubicin by suppressing ERK and mTOR kinases. 13 All of the above-described recent applications of synthetic GIVA cPLA 2 inhibitors highlight the importance of identifying new highly potent inhibitors to regulate the activity of GIVA cPLA 2 . Last year, we reported the development of a novel class of GIVA cPLA 2 inhibitors, namely, 2-oxoesters. 14 2-Oxoester GK452 (6, Figure 1 ), containing a biphenyl system and a free carboxyl group, led to highly potent and selective GIVA cPLA 2 in vitro inhibition (X I (50) 0.000078). The aim of the present work was to further understand the characteristics of 2-oxoesters and explore the possibility of producing more potent GIVA cPLA 2 inhibitors.
■ RESULTS AND DISCUSSION
Synthesis of Inhibitors. To extend the structure−activity relationship studies on 2-oxoester inhibitors, we (a) shortened the length between the activated carbonyl group and the biphenyl functionality, (b) replaced the biphenyl system with a para-alkoxy-substituted phenyl group, and (c) explored the importance of the activated carbonyl group. To this end, a variety of 2-substituted carboxylic acids, required for the target compounds, were synthesized as described in Scheme 1. The synthesis of carboxylic acids 13, 15, and 16, bearing a 4-butoxy-phenyl group, started with the Wadsworth−Horner− Emmons olefination reaction of aldehydes 7a, 7b 15 with triethyl phosphonocrotonate to give the corresponding unsaturated esters 8a,b, which were hydrogenated to compounds 9a,b. The reduction of 9a led to alcohol 10, which subsequently provided cyanohydrin 11. Subsequent treatment with HCl in methanol gave 2-hydroxy methyl ester 12, which was then saponified to 2-hydroxy acid 13 by treatment with aqueous NaOH. Treatment of 12 with the fluorinating agent diethylaminosulfur trifluoride (DAST) 16 resulted in 2-fluoro methyl ester 14, consequently providing 2-fluoro carboxylic acid 15 after saponification. The carboxylic acid 16 was also obtained by alkaline hydrolysis of 9b. The synthesis of 2-hydroxy acid 20 was accomplished by similar procedures starting from aldehyde 17, 17 as depicted in Scheme 2.
The key step in the synthesis of 2-oxoesters was the reaction between cesium salt of 2-hydroxy carboxylic acids with appropriate tert-butyl bromoalkanoate 22a,b 14 (Scheme 3). 2-Hydroxy esters 23a−d, obtained from 2-hydroxy carboxylic acids 13, 20, and the previously synthesized 21, 14 were then oxidized to the corresponding 2-oxoesters 24a−d using the Dess−Martin periodinane reagent. Cleavage of tert-butyl protecting group led to the target compounds 25a−d (Scheme 3).
Likewise, reaction of 2-fluoro carboxylic acid 15 and acid 16 with tert-butyl bromopentanoate (22b) resulted in derivatives 26a,b, and subsequently, after the removal of tert-butyl group, to the desired products 27a,b (Scheme 4). Finally, the synthesis of 2-oxoacid 29 was accomplished as shown in Scheme 5 by saponification of the corresponding 2-oxoester 28 under mild conditions. 
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In Vitro Inhibition of GIVA cPLA 2 , GVIA iPLA 2 , and GV sPLA 2 . All of the new compounds synthesized were tested for in vitro inhibition of human GIVA cPLA 2 , calciumindependent phospholipase A 2 (GVIA iPLA 2 ), and secreted phospholipase A 2 (GV sPLA 2 ) using previously described mixed micelle-based assays. 18−20 The inhibition results are presented in Table 1 , either as percent inhibition or as X I (50) values. At first, the percent of inhibition for each PLA 2 enzyme at a high mole fraction (0.091) of each inhibitor was determined. Then, the X I (50) values were measured for compounds that displayed more than 95% inhibition. The X I (50) is the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50%.
Because it is an important property of GIVA cPLA 2 inhibitors, the Clog P values for all the compounds tested, calculated by ChemDraw, are also included in Table 1 . The Clog P value is a measure of hydrophobicity and represents the calculated partition coefficient in octanol/water on a logarithmic scale.
Inhibitor 6 (GK452) (X I (50) 0.000078) 14 is included in Table 1 for comparison purposes. When the distance between the oxoester functionality and the biphenyl system was decreased from four to two carbon atoms (compound 25c (GK482) and compound 25d (GK483)), the inhibitory potency against GIVA cPLA 2 considerably decreased. This decrease was 1 order of magnitude in the case of a four-carbon linker (compound 25c X I (50) 0.00041), further decreasing (2 orders of magnitude) when the linker was further shortened (25d X I (50) 0.0012). These results are in accordance with our previous results 14 and confirm that the optimum distance between the free carboxyl group and the oxoester functionality corresponds to four carbon atoms. In addition, compound 25c lost the selectivity because the inhibition of GVIA iPLA 2 was observed (X I (50) 0.0030). Thus, the four-carbon linker was maintained for all the other derivatives. The optimum length of the linker may be correlated with stereochemical reasons, rather than hydrophobicity.
Interestingly, when one ring of the biphenyl system was replaced by a para-hexyloxy group, an increase in the inhibitor potency against GIVA cPLA 2 was observed. Compound 25b (GK484) is the most potent inhibitor of GIVA cPLA 2 ever reported with a X I (50) value of 0.000019, 4 times more potent than 6. However, the replacement of the phenyl ring by the hexyloxy group resulted in an increase in the Clog P value (from 4.70 for 6 to 5.37 for 25b). Thus, we shortened the hexyloxy chain to butyloxy one. Compound 25a (GK504) (X I (50) 0.000066) is 3 times less potent than 25b, but still slightly more potent than 6. In addition, its Clog P value (4.31) is lower than 5, which is favorable because Lipinski's "rule of 5" predicts that poor absorption or permeation is more likely when CLog P is greater than 5. 21 Neither 25b nor 25a presented significant inhibition of GVIA iPLA 2 (86 and 77%, respectively, at a high mole fraction 0.091). In our experience, compounds that show inhibition of PLA 2 less than 90% at the highest concentration tested (which corresponds to about 50 μM inhibitor) always exhibit X I (50) values greater than 0.01. 11, 22 The GIVA cPLA 2 inhibitor 25b with a X I (50) 0.000019 is the most potent inhibitor of GIVA cPLA 2 ever reported and is at least 500-fold selective over GVIA iPLA 2 .
To confirm the importance of the oxoester functionality, we removed the activated carbonyl group. Compound 27a (GK505) abolished the inhibitory potency against GIVA cPLA 2 . Because the only structural difference between 27a and 25a is the lack of the carbonyl group, a comparison of the inhibitory potencies of 25a and 27a makes it clear that the carbonyl group of the oxoester functionality is essential for GIVA cPLA 2 inhibition. To explore if an electron-withdrawing group at position 2 could contribute to the inhibitory potency, the fluoro derivative 27b (GK506) was studied. However, again, no inhibition of GIVA cPLA 2 was observed. Finally, 2-oxoacid 29 (GK511) was evaluated in vitro and only a very weak inhibition of GIVA cPLA 2 was recorded (55% at a high mole fraction 0.091). Because this 2-oxoacid is a fragment of 2-oxoester 25a, it is clear that the oxoester functionality is absolutely necessary for the inhibition.
Plasma Stability Studies. Determination of the stability of new chemical entities in plasma is important, as compounds (with the exception of pro-drugs), which rapidly degrade in plasma, generally show poor in vivo performance. 23 The stability of compounds 25a, 25b, and 27a in human plasma was studied in a time-dependent manner. Our aim was to understand the difference between the two highly potent 2-oxoesters GIVA cPLA 2 inhibitors 25a and 25b in comparison to compound 27a lacking the activated carbonyl group. A liquid chromatography-high resolution mass spectrometry (LC-HRMS) method was developed to measure the inhibitor levels in plasma. All of the HRMS spectra were obtained in electrospray ionization (ESI) negative ion mode. The molecular ion of inhibitor 25b (GK484) was recorded at m/ 
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Article z 405.2253 (Figure 2A ), whereas in the MS/MS spectrum ( Figure 2B ), the most intense signal corresponds to the loss of C 5 H 8 O 2 (−100.0524), indicating the fragmentation of the ester bond. The HRMS spectra of inhibitors 25a and 27a are shown in the Supporting Information. In all cases of 2-oxoester inhibitors, the fragmentation of the ester bond was observed. Plasma samples incubated with each inhibitor were taken at 0, 15, 30, and 60 min and the molecular ion of each inhibitor was used to estimate the inhibitor level. The stability results are presented in Figure 2C as percent parent compound remaining at each time point. Inhibitors 25a (GK504) and 25b (GK484), containing the 2-oxo group, are not detectable in the plasma samples after 30 min, in contrast to 27a (GK505), whose percentage remains close to 100% after 1 h. Apparently, the activated carbonyl group of the 2-oxoester functionality of inhibitors 25a and 25b increases the chemical reactivity of the ester bond toward hydrolysis in comparison to the less active simple ester bond of inhibitor 27a. These results indicate that the activated carbonyl group, which is essential for the enzyme inhibition, makes the compounds susceptible to rapid degradation in human plasma. A compound like 27a, lacking the activated carbonyl group, is rather stable in plasma, however lacking the inhibitory properties.
■ CONCLUSIONS
In conclusion, a number of new 2-oxoesters and analogues were synthesized. GK484 is the most potent inhibitor of GIVA cPLA 2 ever reported with a X I (50) value of 0.000019. The study of the in vitro inhibitory activity highlighted the importance of the 2-oxoester group for the inhibitory potency against GIVA cPLA 2 . The stability studies of 2-oxoesters in human plasma indicate that a fine-tuning between the reactivity of the carbonyl group and its stability will be needed in order for 2-oxoesters to be used in vivo as pharmacological agents.
■ EXPERIMENTAL SECTION General. Merck Silica Gel 60254 aluminum plates and Silica Gel 60 (70−230 or 230−400 mesh) were used for thinlayer chromatography and chromatographic purification of products, respectively. For visualizing spots, UV light and/or phosphomolybdic acid was employed. Melting points were estimated by a Buchi 530 apparatus and uncorrected. 1 H, 13 C, and 19 F NMR spectra were recorded on Varian Mercury at 200, 50, and 188 MHz, respectively. CDCl 3 was used as the solvent. Chemical shifts are given in ppm and coupling constants (J) in Hz. Peak multiplicities are typified as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; qt, quintet; and m, multiplet. Dichloromethane was dried by standard procedures and stored over molecular sieves. No further purification of other solvents and chemicals was needed. The HRMS spectra were recorded on a Bruker Maxis Impact QTOF Spectrometer. General Procedure for Synthesis of Unsaturated Esters 8a,b. To a flame-dried, round-bottomed flask containing powdered molecular sieves (1 g), LiOH·H 2 O (1.5 mmol, 36 mg) and a solution of aldehyde 7a,b (1 mmol) in dry THF (10 mL) were added under Ar atmosphere. Triethyl 4-phosphonocrotonate (1.5 mmol, 375 mg) was added and the mixture was left under reflux overnight. The reaction mixture was filtered through celite and the solvent was evaporated under reduced pressure. The products were obtained after trituration with MeOH. General Procedure for Hydrogenation. To a solution of unsaturated esters 8a,b (1 mmol) in EtOH (10 mL), 10% Pd/ C was added and the mixture stirred overnight under H 2 atmosphere. The reaction mixture was filtered through celite and concentrated in vacuo to isolate the saturated product 9a,b.
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Ethyl 5-(4-Butoxyphenyl)pentanoate (9a 6-(4-Butoxyphenyl)-2-hydroxyhexanenitrile (11). To a stirring solution of alcohol 10 (1 mmol, 0.24 g) in dry CH 2 Cl 2 (10 mL), iodobenzene diacetate (1.2 mmol, 0.39 g) and a catalytic amount of TEMPO (10%, 0.024 g) were added and the reaction mixture was left stirring at room temperature for 1 h. The reaction mixture was washed consecutively with 10% aqueous Na 2 S 2 O 3 (10 mL), 10% aqueous NaHCO 3 (10 mL), and brine (10 mL), dried over Na 2 SO 4 , and concentrated in vacuo. The aldehyde was then dissolved in CH 2 Cl 2 (1.5 mL) and 4 N aqueous NaHSO 3 (2 mmol, 0.5 mL) and the mixture was left stirring for 30 min at room temperature. The organic solvent was removed under reduced pressure and H 2 O (1.5 mL) was added. The mixture was cooled down to 0°C and 4 N aqueous KCN (0.5 mL) was added dropwise within 2 h under vigorous stirring, followed by stirring overnight at room temperature. Then, H 2 O (10 mL) was added and extracted with CH 2 Cl 2 (3 × 10 mL). The combined organic layers were washed with brine, dried over Na 2 SO 4 General Procedure for Saponification. To a stirring solution of methyl esters 9b, 12, 14, and 19 (1 mmol) in 1,4-dioxane (10 mL), 2 N aqueous NaOH (2.0 mL) was added and the mixture stirred at room temperature overnight. The solvent was evaporated under reduced pressure and the residue was dissolved in H 2 O (10 mL) and extracted with Et 2 O (3 × 10 mL). The aqueous layer was then acidified with 2 N HCl (4.0 mL) and extracted with EtOAc (3 × 10 mL) followed by drying over Na 2 SO 4 and concentrating in vacuo.
6-(4-Butoxyphenyl)-2-hydroxyhexanoic Acid (13) . Yield 95%; yellowish solid; mp 88−90°C; 1 General Procedure for Synthesis of 23a−d and 26a,b. To a stirred solution of carboxylic acid (1 mmol) in tetrahydrofuran (THF) (6 mL) and 20% aqueous solution CsCO 3 (1.1 mmol, 1.8 mL) were added and left stirring for 10 min at 80°C. The organic solvent was evaporated under reduced pressure and the residue was dissolved in N,N-dimethylformamide (DMF) (15 mL). Subsequently, the appropriate tertbutyl 5-bromoalkanoate, 22a or 22b (1.2 mmol), was added and the reaction mixture was left vigorously stirring under reflux for 72 h. The reaction mixture was concentrated in vacuo and then water (20 mL) was added and extracted with EtOAc (2 × 20 mL). The organic phase was dried (Na 2 SO 4 ) and concentrated under reduced pressure. The residue was purified by flash column chromatography using EtOAc/ petroleum ether (bp 40−60°C) 3:7 or 2:8. General Procedure for Oxidation of 2-Hydroxy Esters. To a stirring solution of 2-hydroxy esters 12 and 23a−d (1 mmol) in dry CH 2 Cl 2 (10 mL), Dess−Martin periodinane (1.1 mmol, 0.47 g) was added and the reaction mixture was stirred for 1.5 h at room temperature. The organic phase was washed with a mixture of Na 2 S 2 O 3 10% and NaHCO 3 10% (15 mL, 1:1, v/v) and then with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was purified by flash column chromatography using EtOAc−petroleum ether (bp 40−60°C) 2:8 as eluent.
5-(tert-Butoxy)-5-oxopentyl 6-(4-butoxyphenyl)-2-hydroxyhexanoate (23a
5-(tert-Butoxy)-5-oxopentyl 6-(4-butoxyphenyl)-2-oxohexanoate (24a General Procedure for Cleavage of tert-Butyl Protecting Group. A solution of tert-butyl esters 24a−d, 26a,b (1 mmol) in CH 2 Cl 2 (5 mL), and trifluoroacetic acid (TFA) (5 mL) was stirred for 1 h at room temperature. The organic solvent was evaporated under reduced pressure and then toluene (5 mL) was added and re-evaporated twice. The product was purified by precipitation with a mixture of EtOAc and petroleum ether (bp 40−60°C) (5:95, v/v) or by column chromatography (CH 2 Cl 2 −MeOH, 95:5).
5-((6-(4-Butoxyphenyl)-2-oxohexanoyl)oxy)pentanoic Acid (25a). Yield 72%; white solid; mp 55−58°C. 
